SG Americas Securities LLC Has $1.30 Million Position in Organon & Co. $OGN

SG Americas Securities LLC trimmed its stake in shares of Organon & Co. (NYSE:OGN) by 21.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 216,319 shares of the company’s stock after selling 59,767 shares during the quarter. SG Americas Securities LLC owned approximately 0.08% of Organon & Co. worth $1,296,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in OGN. Foster Dykema Cabot & Partners LLC acquired a new stake in shares of Organon & Co. during the 3rd quarter valued at $29,000. Farther Finance Advisors LLC increased its holdings in Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. in the 4th quarter worth about $44,000. Kestra Advisory Services LLC acquired a new position in Organon & Co. in the 4th quarter worth about $47,000. Finally, Empowered Funds LLC bought a new position in Organon & Co. in the fourth quarter valued at about $74,000. Institutional investors own 77.43% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Lynette Holzbaur purchased 26,448 shares of the stock in a transaction on Wednesday, May 6th. The stock was purchased at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.62% of the company’s stock.

Organon & Co. Stock Up 0.1%

Shares of OGN opened at $13.56 on Friday. The stock’s 50-day moving average price is $13.27 and its two-hundred day moving average price is $9.53. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.60. The company has a market capitalization of $3.56 billion, a PE ratio of 14.59, a PEG ratio of 1.25 and a beta of 1.54. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 EPS. On average, analysts anticipate that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, May 11th. Organon & Co.’s dividend payout ratio is currently 8.60%.

Analyst Ratings Changes

Several research firms have recently weighed in on OGN. Weiss Ratings upgraded Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. BNP Paribas Exane reiterated a “neutral” rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Organon & Co. currently has an average rating of “Reduce” and an average target price of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.